Aducanumab (BIIB037), A selective human immunoglobulin gamma-1 (IgG1) monoclonal antibody, targets the clustered form of amyloid beta (Abeta). Aducanumab shows brain permeability and may be used to treat Alzheimers disease (AD).
CAS Number:
[1384260-65-4]
Target:
Beta Amyloid
* VAT and and shipping costs not included. Errors and price changes excepted